Abselion Launches AAVX and AAV9 Quantification Kits

Abselion, a life sciences technology company focused on simplifying biomolecule quantification, has expanded its product offering with the launch of the AAVX Total Capsid Quantification Kit and the AAV9 Total Capsid Quantification Kit.

Both kits are designed for use with its Amperia benchtop quantification platform and include Thermo Fisher Scientific’s CaptureSelect affinity reagents. Combining these reagents with Abselion’s consistent assay format reduces the need for in-house optimization. These kits offer researchers working in adeno-associated virus (AAV) development and characterization a more streamlined and accessible workflow to generate reproducible titre measurements across a broad range of serotypes and process conditions.

Each kit is supplied in a ready-to-use format, including sensor strips, assay plates, matched detection reagents, and assay buffers for the binding and detection steps.

Abselion has entered into a licensing agreement with Thermo Fisher Scientific to incorporate CaptureSelect affinity reagents into its AAV quantification kits. CaptureSelect technology is based on recombinant single-domain antibodies designed for high target specificity, low cross-reactivity, and consistent batch performance to ensure robust titre quantification. With the integration of these reagents, the new kits advance Abselion’s AAV assay format, bringing improved performance and broader serotype applicability.

Both kits use a sandwich-style immunoassay format, in which biotin- and HRP-conjugated CaptureSelect antibodies are sequentially applied to bind AAV capsids. The resulting signal is detected electrochemically using Amperia sensor strips, enabling accurate quantitative detection across a range of AAV sample types and concentrations.

The AAVX Total Capsid Quantification Kit includes CaptureSelect Anti-AAVX Biotin and HRP Conjugates, enabling broad serotype coverage including AAV1–8 and AAVrh10. The AAV9 Total Capsid Quantification Kit incorporates CaptureSelect Anti-AAV9 Biotin and HRP Conjugates for focused quantification of AAV9 particles.

Dr. Ruizhi Wang, CEO and Founder, Abselion, said: “Reliable quantification of total AAV capsid concentration is key to maintaining consistency and supporting informed decision-making. The integration of Thermo Fisher Scientific’s CaptureSelect reagents strengthens the performance of Abselion’s AAV kits and reflects our focus on making high-quality titre measurement simpler and more accessible. With these additions, Amperia offers researchers a ready-to-use solution that combines trusted reagent technologies with a streamlined assay format, enabling reliable quantification across a wider range of serotypes and development workflows.”